Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...